Immunohistochemical Detection of the Membrane and Fluid‐phase Terminal Complement Complexes C5b‐9(m) and SC5b‐9

Activation of the terminal pathway of complement on a membrane results in the generation of the membrane‐damaging terminal C5b‐9(m) complement complex, whereas the non‐lytic water‐soluble SC5b‐9 complex is formed when complement is activated in the fluid phase. Both forms of the terminal complement complex (TCC) can be immunohistochemically detected. but not distinguished, by antibodies recognizing neoantigens in the complexes. By means of monoclonal antibodies against C9 neoantigens and against the S‐protein. it was demonstrated that deposits of the TCC in tissue sections may be either in the form of C5b‐9(m) or SC5b‐9. The consequences of this for the interpretation of the histochemical data and the terminology of the two complexes are discussed.

[1]  M. Kazatchkine,et al.  Immunohistochemical analysis of C3 cleavage fragments, factor H, and the C5b-9 terminal complex of complement in de novo membranous glomerulonephritis occurring in patients with renal transplant. , 1986, Clinical nephrology.

[2]  D. Mathey,et al.  Deposition of the terminal C5b-9 complement complex in infarcted areas of human myocardium. , 1986, Journal of immunology.

[3]  M. Kazatchkine,et al.  Immunohistochemical study of the C5b-9 complex of complement in human kidneys. , 1986, Kidney international.

[4]  H. Rus,et al.  Immunohistochemical detection of the terminal C5b-9 complement complex in children with glomerular diseases. , 1986, Clinical and experimental immunology.

[5]  H. Rus,et al.  Immunoelectron-microscopic localization of the terminal C5b-9 complement complex in human atherosclerotic fibrous plaque. , 1986, Atherosclerosis.

[6]  J. Tschopp,et al.  Antigenic crossreactivity of the alpha subunit of complement component C8 with the cysteine-rich domain shared by complement component C9 and low density lipoprotein receptor. , 1986, Proceedings of the National Academy of Sciences of the United States of America.

[7]  S. Bhakdi,et al.  C5b-9 assembly: average binding of one C9 molecule to C5b-8 without poly-C9 formation generates a stable transmembrane pore. , 1986, Journal of immunology.

[8]  W. Couser,et al.  Complement membrane attack complex stimulates production of reactive oxygen metabolites by cultured rat mesangial cells. , 1986, The Journal of clinical investigation.

[9]  J. Mendell,et al.  Microvascular deposition of complement membrane attack complex in dermatomyositis. , 1986, The New England journal of medicine.

[10]  B. Dahlbäck,et al.  Localization of vitronectin (S-protein of complement) in normal human skin. , 1986, Acta dermato-venereologica.

[11]  D. Jenne,et al.  Molecular cloning of S‐protein, a link between complement, coagulation and cell‐substrate adhesion. , 1985, The EMBO journal.

[12]  H. Rus,et al.  Immunohistochemical localization of the terminal C5b-9 complement complex in human aortic fibrous plaque. , 1985, Atherosclerosis.

[13]  J. Tschopp,et al.  Monoclonal Antibodies Recognizing a Neoantigen of Poly(C9) Detect the Human Terminal Complement Complex in Tissue and Plasma , 1985, Scandinavian journal of immunology.

[14]  D. Jenne,et al.  Monoclonal antibodies against neoantigens of the terminal C5b-9 complex of human complement , 1985, Bioscience reports.

[15]  A. Michael,et al.  Membrane attack complex of complement in dermatitis herpetiformis. , 1985, Archives of dermatology.

[16]  M. Betz,et al.  Macrophages release arachidonic acid, prostaglandin E2, and thromboxane in response to late complement components. , 1984, Journal of immunology.

[17]  E. Podack,et al.  Membrane attack by complement. , 1984, Molecular immunology.

[18]  A. Michael,et al.  Deposition of the membrane attack complex of complement in bullous pemphigoid. , 1984, The Journal of investigative dermatology.

[19]  M. Shin,et al.  Consequences of cell membrane attack by complement: release of arachidonate and formation of inflammatory derivatives. , 1983, Proceedings of the National Academy of Sciences of the United States of America.

[20]  G. Biesecker.  Membrane attack complex of complement as a pathologic mediator. , 1983, Laboratory investigation; a journal of technical methods and pathology.

[21]  S. Bhakdi,et al.  Membrane damage by complement. , 1983, Biochimica et biophysica acta.

[22]  A. Michael,et al.  Neoantigen of the polymerized ninth component of complement. Characterization of a monoclonal antibody and immunohistochemical localization in renal disease. , 1983, The Journal of clinical investigation.

[23]  M. Howell,et al.  Direct lysis of erythrocytes by EGTA and calcium ions: implications for assessing complement activation by parasites , 1983, Parasite immunology.

[24]  E. Ruoslahti,et al.  Serum spreading factor (vitronectin) is present at the cell surface and in tissues. , 1983, Proceedings of the National Academy of Sciences of the United States of America.

[25]  M. Ziskind,et al.  Cutaneous localization of the membrane attack complex in discoid and systemic lupus erythematosus. , 1982, The New England journal of medicine.

[26]  D. Koffler,et al.  Renal localization of the membrane attack complex in systemic lupus erythematosus nephritis , 1981, The Journal of experimental medicine.

[27]  S. Bhakdi,et al.  Immunochemical analyses of membrane-bound complement. Detection of the terminal complement complex and its similarity to "intrinsic" erythrocyte membrane proteins. , 1975, Biochimica et biophysica acta.

[28]  H. Müller-Eberhard,et al.  Neoantigens of the membrane attack complex of human complement. , 1975, Proceedings of the National Academy of Sciences of the United States of America.